205 related articles for article (PubMed ID: 21988334)
21. The pharmacokinetics of darexaban are not affected to a clinically relevant degree by rifampicin, a strong inducer of P-glycoprotein and CYP3A4.
Groenendaal D; Strabach G; Garcia-Hernandez A; Kadokura T; Heeringa M; Mol R; Eltink C; Onkels H
Br J Clin Pharmacol; 2013 Feb; 75(2):440-9. PubMed ID: 22642721
[TBL] [Abstract][Full Text] [Related]
22. Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
Lee J; Moy S; Meijer J; Krauwinkel W; Sawamoto T; Kerbusch V; Kowalski D; Roy M; Marion A; Takusagawa S; van Gelderen M; Keirns J
Clin Drug Investig; 2013 Jun; 33(6):429-40. PubMed ID: 23625188
[TBL] [Abstract][Full Text] [Related]
23. Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Lassen U; Miller WH; Hotte S; Evans TR; Kollmansberger C; Adamson D; Nielsen DL; Spicer J; Chen E; Meyer T; Brown K; Rafi R; Sawyer MB
Cancer Chemother Pharmacol; 2013 Feb; 71(2):543-9. PubMed ID: 23196640
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole.
Martin P; Oliver S; Robertson J; Kennedy SJ; Read J; Duvauchelle T
Drugs R D; 2011; 11(1):37-51. PubMed ID: 21410294
[TBL] [Abstract][Full Text] [Related]
25. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
Hatorp V; Hansen KT; Thomsen MS
J Clin Pharmacol; 2003 Jun; 43(6):649-60. PubMed ID: 12817528
[TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
[TBL] [Abstract][Full Text] [Related]
27. Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Martin P; Gillen M; Millson D; Oliver S; Brealey C; Grossbard EB; Baluom M; Lau D; Sweeny D; Mant T; Craven K
Drugs R D; 2016 Mar; 16(1):81-92. PubMed ID: 26739683
[TBL] [Abstract][Full Text] [Related]
28. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.
Tanaka C; Yin OQ; Smith T; Sethuraman V; Grouss K; Galitz L; Harrell R; Schran H
J Clin Pharmacol; 2011 Jan; 51(1):75-83. PubMed ID: 20702754
[TBL] [Abstract][Full Text] [Related]
29. Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.
Bernard A; Vaccaro N; Acharya M; Jiao J; Monbaliu J; De Vries R; Stieltjes H; Yu M; Tran N; Chien C
Clin Pharmacol Drug Dev; 2015 Jan; 4(1):63-73. PubMed ID: 27128004
[TBL] [Abstract][Full Text] [Related]
30. The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator.
Elgart A; Greenblatt DJ; Loupe PS; Zur AA; Weiss S; Mimrod D; Spiegelstein O
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):1015-1024. PubMed ID: 32237115
[TBL] [Abstract][Full Text] [Related]
31. Effects of ketoconazole and valproic acid on the pharmacokinetics of the next generation NNRTI, lersivirine (UK-453,061), in healthy adult subjects.
Langdon G; Davis J; Layton G; Chong CL; Weissgerber G; Vourvahis M
Br J Clin Pharmacol; 2012 May; 73(5):768-75. PubMed ID: 22040521
[TBL] [Abstract][Full Text] [Related]
32. In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects.
Shoaf SE; Ohzone Y; Ninomiya S; Furukawa M; Bricmont P; Kashiyama E; Mallikaarjun S
J Clin Pharmacol; 2011 May; 51(5):761-9. PubMed ID: 20679500
[TBL] [Abstract][Full Text] [Related]
33. Effect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal system.
Kapil RP; Cipriano A; Michels GH; Perrino P; O'Keefe SA; Shet MS; Colucci SV; Noveck RJ; Harris SC
Clin Drug Investig; 2012 Sep; 32(9):583-92. PubMed ID: 22845044
[TBL] [Abstract][Full Text] [Related]
34. Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs.
Zhou X; Gao ZW; Meng J; Chen XY; Zhong DF
Acta Pharmacol Sin; 2013 Nov; 34(11):1420-6. PubMed ID: 24056704
[TBL] [Abstract][Full Text] [Related]
35. Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
Mohamed MF; Jungerwirth S; Asatryan A; Jiang P; Othman AA
Br J Clin Pharmacol; 2017 Oct; 83(10):2242-2248. PubMed ID: 28503781
[TBL] [Abstract][Full Text] [Related]
36. Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers.
Li A; Yeo K; Welty D; Rong H
Paediatr Drugs; 2018 Apr; 20(2):181-194. PubMed ID: 29098603
[TBL] [Abstract][Full Text] [Related]
37. The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
Xu H; O'Gorman M; Tan W; Brega N; Bello A
Eur J Clin Pharmacol; 2015 Dec; 71(12):1441-9. PubMed ID: 26381275
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
Wang X; Wang J; Arora S; Hughes L; Christensen J; Lu S; Zhang ZY
J Clin Pharmacol; 2019 Apr; 59(4):488-499. PubMed ID: 30422319
[TBL] [Abstract][Full Text] [Related]
39. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers.
Abel S; Jenkins TM; Whitlock LA; Ridgway CE; Muirhead GJ
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):38-46. PubMed ID: 18333864
[TBL] [Abstract][Full Text] [Related]
40. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
